A cure for SCD (sickle cell disease) has long remained to be a far-fetched dream for the medical community. This is ironical, since for decades now, the medical fraternity is very well aware of the single gene mutation in the beta-chain of hemoglobin that leads to this hemoglobinopathy. The area remains woefully underserved, with very limited treatment options.
In this backdrop, Global Blood Therapeutics (GBT) is working towards modifying the course of the disease. While the company's lead investigational asset, Voxelotor, cannot be exactly called a cure for the disease, it may, nevertheless,